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Abstract
Background: In 2016, persons aged 13–29 years represented 23.1% of the U.S. population, yet 
accounted for 41.7% of HIV diagnoses. Racial/ethnic minorities are disproportionally affected by 
HIV. Sustaining viral suppression helps persons living with diagnosed HIV infection (PLWDH) 
stay healthy and reduces the risk of transmitting HIV. We examined racial/ethnic disparities in 
sustained viral suppression and transmission risk potential among PLWDH aged 13–29 years.
Methods: We analyzed data from the National HIV Surveillance System reported through 
December 2018 from 42 jurisdictions with complete laboratory reporting. We included persons 
aged 13–29 years who received an HIV diagnosis by December 31, 2015, most recently resided in 
one of the 42 jurisdictions, and were alive at the end of 2016. Sustained viral suppression was 
defined as viral load <200 copies/mL for all tests in 2016. Transmission risk potential was 
estimated using the number of days with viral loads >1,500 copies/mL.
Results: Of the 90,812 PLWDH aged 13–29 years included in the analysis, 41.5% had sustained 
viral suppression in 2016. Across age, sex, and most transmission categories, blacks had the 
lowest prevalence of sustained viral suppression. Among the 28,154 who were in care but without 
sustained viral suppression, the average number of days with viral load >1,500 copies/mL was 206 
days (56.4% of the 12-month period).
Conclusion: Sustained viral suppression was suboptimal and transmission risk potential was 
high for PLWDH aged 13–29 years. Racial/ethnic disparities were apparent, calling for 
strengthening tailored interventions to improve care outcomes.
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INTRODUCTION
Advances in HIV prevention and treatment allow for a once-in-a-generation opportunity to 
end the HIV epidemic in the United States.1 Using data to identify disparities can effectively 
guide prevention, treatment and care efforts for achieving the goal of ending the HIV 
epidemic. Adolescents and young adults are disproportionately affected by HIV in the 
Unites States. In 2016, persons aged 13–29 years represented 23.1% of the U.S. population,2 
yet accounted for 41.7% of HIV diagnoses.3 HIV diagnosis rates per 100,000 population 
varied substantially among those aged 13–14 years (0.3), 15–19 years (8.0), 20–24 years 
(30.7), and 25–29 years (34.6).3 Additionally, HIV diagnosis rates were 3 to 17 times higher 
among blacks/African Americans (blacks), Hispanic/Latinos and other races than among 
whites.3 Of HIV infections diagnosed in 2016 among persons aged 13–29 years, 78.5% were 
attributed to male-to-male sexual contact; of which 48.8% were among black men who have 
sex with men (MSM), 26.9% were among Hispanic/Latino MSM, and 18.0% were among 
white MSM.3
Simpler, more potent and tolerable antiretroviral therapy (ART) has helped many persons 
living with diagnosed HIV infection (PLWDH) to achieve and sustain viral suppression, stay 
healthy, reduce mortality, and decrease the risk of transmitting HIV.4–7 However, adolescents 
and young adults are the least likely of any age group to be linked to care in a timely 
manner,8 to be prescribed ART,9 and to achieve and sustain viral suppression.8–10 Identified 
barriers to care and treatment include transition to adult care, ART management challenges, 
lack of health insurance, inexperience with and infrequent access to medical care, 
dissatisfaction with the health team/system, perceived stigma, illicit substance use, mental 
health issues, lack of support, behavioral and conduct problems, poverty, low education, 
homelessness, and living in more disadvantaged areas.11–14 Youth and young adults with 
perinatally acquired HIV may have unique experiences and barriers to care and treatment 
compared to those with behaviorally acquired HIV.11 Racial/ethnic minority youth and 
young adults at various bio-psychosocial and cognitive developmental stages may also 
experience different barriers to HIV care, ART use, and viral suppression11–14 as each race 
and ethnicity has unique cultural values, beliefs and practices that may contribute to 
disparities in HIV care. Without sustaining viral suppression, adolescent and young adults 
may experience longer time with a viral load level (e.g., >1,500 copies/mL) which increases 
the risk for transmitting HIV.15
Several studies examined viral suppression among racial/ethnic groups15–17 and among 
young age groups.18–20 There is no study to our knowledge specifically focused on PLWDH 
aged 13–29 years of different racial/ethnic groups and examines sustained viral suppression 
and transmission risk potential by narrower age groups, sex, behavioral transmission 
categories, and perinatally acquired HIV. In this report, we used CDC’s National HIV 
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Surveillance System (NHSS) to conduct more refined analyses to gauge disparities and 
identify needs for tailored interventions.
METHODS
We used NHSS data through December 2018 from 42 jurisdictions that had complete 
laboratory reporting. The 42 jurisdictions are Alabama, Alaska, California, Colorado, 
Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Illinois, Indiana, 
Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, 
Missouri, Montana, Nebraska, New Hampshire, New Mexico, New York, North Carolina, 
North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, South Carolina, South Dakota, 
Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. 
These jurisdictions accounted for 89.5% of all persons aged 13–29 years living with 
diagnosed HIV infection at year-end 2016 in the United States. The analytic cohort included 
persons aged 13–29 years who received an HIV diagnosis by December 31, 2015, most 
recently resided in one of the 42 jurisdictions, and were alive at the end of 2016.
Sustained viral suppression was defined as all viral load test results <200 copies/mL in 
2016.15 For persons who had only one viral load test in 2016, sustained viral suppression 
was defined as a viral load test result of <200 copies/mL for the 2016 test and for the last 
viral load test in 2015. Persons with no viral load tests in 2016 were presumed not 
suppressed.15 All persons aged 13–29 years with HIV diagnosed through 2015 who were 
living at the end of 2016 were included in the denominator for determining the percentage 
with sustained viral suppression.
Among persons who received HIV medical care (defined as having at least one CD4 or viral 
load test in 2016)8 without sustained viral suppression in 2016 (i.e., not all viral load test 
results <200 copies/mL), we estimated HIV transmission potential based on the number of 
days that a person’s viral load was >1,500 copies/mL.15,21,22
Both outcomes were stratified by race/ethnicity and examined by age, sex, behavioral 
transmission category, and perinatally acquired HIV. We categorized race/ethnicity into the 
following groups: black, Hispanic/Latino, white, and other. Using the standard method in 
HIV surveillance reports,3,8 Hispanics/Latinos can be of any race. The Other category 
includes American Indians/Alaska Natives, Asians, Native Hawaiians/other Pacific Islanders 
and persons reporting multiple races.
Results:
The analytic cohort consisted of 90,812 PLWDH aged 13–29 years, including 55.3% blacks, 
22.0% Hispanic/Latinos, 15.9% whites, and 6.8% other races (Table 1). The majority were 
male (80.4%), MSM (68.9%), aged 25–29 years (64.3%), and persons with behaviorally 
acquired HIV (91.7%). The median number of viral load tests in 2016 was two, with 52,677 
(58.0%) persons having two or more tests, 13,200 (14.5%) having one test, and 24,935 
(27.5%) having no test in 2016. The percentage of persons without a viral load test in 2016 
was 29.5% among blacks, 25.2% among Hispanics/Latinos, 25.6% among whites, and 
22.8% among others.
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Of the 90,812 PLWDH aged 13–29 years, 41.5% had sustained viral suppression in 2016 
(Table 1). Overall, the lowest prevalence of sustained viral suppression was among blacks 
(36.1%), compared with Hispanics/Latinos (46.7%), others (47.3%), and whites (50.8%). 
The prevalence of sustained viral suppression varied by age within racial/ethnic groups. 
Among blacks and Hispanics/Latinos, persons aged 20–24 years had the lowest prevalence 
of sustained viral suppression (34.1% and 43.7%) compared to the other three age groups. 
For whites, PLWDH aged 13–14 years and 15–19 years had the lowest prevalence of 
sustained viral suppression (both 48.6%). Among persons of other races, those aged 15–19 
years had the lowest prevalence of sustained viral suppression (42.0%). Across all racial/
ethnic groups, more males than females had sustained viral suppression in 2016 (43.0% vs. 
35.6% overall). MSM had the highest prevalence of sustained viral suppression (44.3%), 
whereas persons who inject drugs (PWID) had the lowest prevalence of sustained viral 
suppression overall (30.9% for males, 32.0% for females) and within each of the racial/
ethnic groups. Prevalence of sustained viral suppression was higher among those with 
behaviorally acquired HIV than those with perinatally acquired HIV (42.2% vs. 34.6%). 
This pattern was seen within each of the racial/ethnic groups. Across all age groups, sex, 
behavioral transmission categories (except Other transmission category), and perinatally 
acquired HIV, blacks had the lowest prevalence of viral suppression compared to the other 
three racial/ethnic groups. Among all subgroups across racial/ethnic groups and selected 
demographic characteristics, black PWID had the lowest prevalence of sustained viral 
suppression (24.4% for males and 27.5% for females).
About one third (31.0%; 28,154/90,812) received HIV medical care but without sustained 
viral suppression in 2016. Among the 28,154 PLWDH, the average number of days with 
viral loads >1,500 copies/mL was 206 days (56.4% of the 12-month period, Table 2). Blacks 
experienced a longer period (213 days, 58.3% of the 12-month period) with viral loads 
>1,500 copies/mL, than did others (199 days, 54.5%), Hispanics/Latinos (198 days, 54.2%) 
and whites (184 days, 50.4%). Across all racial/ethnic groups, female PWID experienced the 
longest period with viral loads >1,500 copies/mL. The number of days with viral load 
>1,500 copies/mL were comparable between those with perinatally and behaviorally 
acquired HIV.
DISCUSSION
Among PLWDH aged 13–29 years, about two in five persons (41.5%) achieved sustained 
viral suppression in 2016. More than one in four (27.5%) did not have a viral load test in 
2016 which, in part, may be due to inadequate HIV care. Racial/ethnic disparities in 
sustained viral suppression were apparent across age, sex, most behavioral transmission 
categories, and perinatally acquired HIV. Black youths and young adults had the lowest 
prevalence of sustained viral suppression. Among those who were in care but did not sustain 
viral suppression, blacks experienced a longer time with viral loads >1,500 copies/mL than 
other racial/ethnic groups, a circumstance that may increase transmission risk.
While MSM, in general, had the highest prevalence of sustained viral suppression across all 
transmission categories, black MSM who accounted for 53.8% of MSM aged 13–29 years 
living with diagnosed HIV infection had the most suboptimal outcome with only 38.0% 
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sustained viral suppression. Evidence from the Medical Monitoring Project (MMP) showed 
that ART prescription increased among young black men during 2009–2014; however, there 
were no significant increases in ART adherence or sustained viral suppression during the 
same period.23 MMP data also showed that a high proportion of young black men were 
living at or below the poverty level, were homeless, and had higher prevalence of unmet 
need for transportation assistance, housing, and food and nutrition.23,24
Other subgroups who had low prevalence of sustained viral suppression and warrant 
attention are male and female PWID and persons who acquired HIV perinatally. Although 
PWID represented 2.6% of PLWDH aged 13–29 years, fewer than one in three male and 
female PWID sustained viral suppression in 2016. Similarly, around one in three PLWDH 
with perinatally acquired HIV sustained viral suppression. Suboptimal outcomes may be the 
result of loss of care in transitioning to adult care, burn out, stigma, mental health 
comorbidities, poor adherence, and illicit substance use which are common in these groups.
11,12,25–27
Taken together, our findings indicate that PLWDH aged 13–29 years have not fully benefited 
from HIV care and treatment. Sustaining viral suppression is a challenge across the HIV 
population.22 It can be even more challenging for PLWDH aged 13–29 years who are less 
experience with medical care than older adults and who face additional barriers associated 
with various bio-psychosocial and cognitive developmental stages.11–14 Ending the HIV 
epidemic is unlikely to be achieved unless effective programs are established and expanded 
to improve sustained viral suppression and decrease disparities among PLWDH aged 13–29 
years. Two evidence-based interventions (EBIs)28 show that a centralized service model with 
a multi-disciplinary team of adolescent care providers, social workers, and case managers29 
and a tightly coordinated medical-social support network30 are effective in improving 
retention in HIV care by delivering developmentally and culturally appropriate care and 
services that address medical, physical, psychosocial, environmental, and financial needs of 
adolescent and young adult PLWDH. Another strategy that has shown promise in improving 
medication adherence, care visit, and vial suppression is the use of mobile phone technology 
and social media.31,32 PLWDH aged 13–29 years could also benefit from education about 
Undetectable = Untransmittable (U=U) to further strengthen motivation to initiate and 
adhere to ART.33 Understanding there is effectively no risk of transmitting HIV through sex 
for persons taking ART as prescribed and achieving and maintaining viral suppression might 
alleviate potential self-stigma surrounding potential transmission for PLWDH aged 13–29 
years with sustained viral suppression.33 Given that adolescents and young adults have the 
lowest knowledge of HIV status,34 wide dissemination of U=U messages to this group might 
facilitate discussion of HIV prevention options (e.g., pre-exposure prophylaxis), reduce HIV 
stigma, and motivate HIV testing among those who are uncertain about their serostatus.33 
Improving sustained viral suppression and reducing HIV transmission risk among PLWDH 
aged 13–29 years is possible. However, it will require implementing and scaling up 
developmentally appropriate EBIs, wide dissemination of U=U message, involvement of 
clinicians and services providers, transitioning youth to adult care and services, and utilizing 
innovative strategies (e.g., mobile technology, mHealth) to reach and engage this age group.
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Our results are subject to the following limitations. First, analyses were limited to 42 
jurisdictions with complete laboratory reporting which might not be representative of all 
persons aged 13–29 years living with diagnosed HIV infection in the United States. Second, 
ART initiation and status are not well captured in NHSS, therefore patient-level ART data 
are not available. Third, transmission risk potential was estimated for PLWDH who had an 
indication of care (≥1 CD4 or viral load laboratory test). Having a laboratory test does not 
necessarily indicate whether the person received appropriate HIV medical care or not.
In summary, our findings highlight suboptimal outcomes of sustained viral suppression and 
transmission risk potential among PLWDH aged 13–29 years of different racial/ethnic 
groups. Disparities are apparent, calling for strengthening tailored interventions that are 
developmentally and culturally appropriate in addressing barriers to care and unmet needs of 
PLWDH aged 13–29 years.
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